Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 7/20 | 0.48 |
| ▸ | ACACA | Q13085 | 7/20 | 0.48 |
| ▸ | BACE1 | P56817 | 10/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14701983 | 0.85 | ACACB (0.35) | ACACBACACASLC6A3 | |
| SCHEMBL3434210 | 0.77 | ACACB (0.43) | ACACBACACA | |
| SCHEMBL14700724 | 0.70 | ACACB (0.71) | ACACBACACABACE1SLC6A4SLC6A3 | |
| SCHEMBL1941588 | 0.70 | ACACB (0.46) | ACACBACACABACE1SLC6A4SLC6A3 | |
| SCHEMBL1941586 | 0.70 | ACACB (0.46) | ACACBACACABACE1SLC6A4SLC6A3 | |
| SCHEMBL2354375 | 0.70 | ACACB (0.71) | ACACBACACABACE1SLC6A4SLC6A3 | |
| SCHEMBL2353412 | 0.70 | ACACB (0.71) | ACACBACACABACE1SLC6A4SLC6A3 | |
| SCHEMBL1942867 | 0.69 | ACACB (0.50) | ACACBACACABACE1SLC6A4SLC6A3 | |
| SCHEMBL3432953 | 0.69 | ACACB (0.38) | ACACBACACA | |
| SCHEMBL8280541 | 0.66 | ACACB (0.63) | ACACBACACABACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130040935-A1 | CYCLIC KETO-ENOLS FOR THERAPY | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-02-14 | — | — | US | disclosed |
| US-20120129833-A1 | CYCLIC KETOENOLS FOR THERAPY | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040935-A1 | CYCLIC KETO-ENOLS FOR THERAPY | AKR1B1, AKR1C3, AKR1A1 | ACACB 310/4885ACACA 541/4885BACE1 3453/4885 |
| US-20120129833-A1 | CYCLIC KETOENOLS FOR THERAPY | CYP46A1, LIPC, CYP27A1 | ACACB 85/4885ACACA 90/4885BACE1 3418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.